CorMedix Inc. (NASDAQ: CRMD)

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The company's lead product is DefenCath, an antimicrobial catheter lock solution approved to reduce catheter related bloodstream infections in hemodialysis patients. DefenCath combines taurolidine and heparin to provide antimicrobial and anticoagulant activity in a single formulation. The product received FDA approval in November 2023 and was launched commercially in April 2024 for inpatient hemodialysis and in July 2024 for outpatient hemodialysis. In August 2025, CorMedix acquired Melinda Therapeutics, adding six marketed infectious disease products and a cardiovascular product to its portfolio. The combined offerings target infections and cardiovascular care in hospital and outpatient settings.

CorMedix generates revenue primarily through the sale of its pharmaceutical products to healthcare providers. DefenCath is sold to outpatient dialysis clinics and inpatient hospitals for use as a catheter lock solution and represents the largest contributor to the company's net sales. The Melinta portfolio contributes revenue from anti infective agents such as REZZAYO, MINOCIN IV, VABOMERE, KIMYRSA, ORBACTIV, and BAXDELA, as well as the cardiovascular product TOPROL XL. These products are distributed to hospitals, emergency departments, outpatient clinics, and home infusion centers where they are used to treat serious bacterial and fungal infections or manage hypertension. Revenue also depends on the extent of third party payer coverage and reimbursement rates from programs such as Medicare and Medicaid.

CorMedix holds a differentiated position in the U. S. market for antimicrobial catheter lock solutions, as DefenCath is the only FDA approved product in this category. This exclusivity provides a competitive advantage over heparin only lock solutions that lack antimicrobial activity. In the broader anti infective market, the company competes with large pharmaceutical firms and generic manufacturers, but its products such as REZZAYO and VABOMERE offer distinct dosing or mechanism benefits that align with antimicrobial stewardship guidelines. The company's strategy emphasizes demonstrating clinical and economic value through real world evidence to support formulary adoption and reimbursement. DefenCath has been shown in clinical studies to reduce the risk of catheter related bloodstream infection by 71%. Additionally, the Melinta portfolio includes products with once weekly or extended dosing schedules that simplify administration and reduce burden on healthcare staff.

CorMedix serves dialysis centers, hospitals, outpatient clinics, and home infusion providers across the United States. The company has entered into multi year supply agreements with a large dialysis organization and several mid sized dialysis operators, covering an estimated 60% of the outpatient dialysis market. Specific customer names are not disclosed in the filing. In addition, its anti infective products are prescribed by infectious disease specialists, hospitalists, and critical care physicians in acute care settings. The company also supports home infusion therapy for patients receiving anti infective agents outside the hospital, expanding its reach into the post acute care continuum.